Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.20), $0.11 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $42.8 million versus the consensus estimate of $36.21 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2024 revenue of $145-160 million, versus the consensus of $145.3 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.